Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT04794699 | Study of IDE397 in Participants With Solid Tumors Harboring MTAP Deletion | PHASE1 | ACTIVE NOT_RECRUITING | 169 | — | — | Apr 14, 2021 | Feb 4, 2027 | Apr 9, 2026 | 37 | United States, Australia +5 |
Incidence of DLTs of IDE397 will be determined
Incidence of DLTs of IDE397 in a combination setting will be determined
MTD and RP2D of IDE397 will be determined
MTD and RP2D of IDE397 in a combination setting will be determined
Objective Response Rate (ORR) and Duration of Response (DoR)
| Arm | Type | Description |
|---|---|---|
| Part 1: Dose Escalation Monotherapy (Solid Tumors) | EXPERIMENTAL | - |
| Part 2: Monotherapy Dose Expansion (NSCLC and Urothelial) | EXPERIMENTAL | - |
| Part 5: Combination Dose Escalation with sacituzumab govitecan (SG) (NSCLC and Urothelial) | EXPERIMENTAL | - |
| Part 6: Combination Dose Expansion with sacituzumab govitecan (SG) (NSCLC and Urothelial) | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| IDE397 | DRUG | IDE397 dosed orally |
| Sacituzumab govitecan | DRUG | Intravenous infusion |
Inclusion Criteria: * Participant must be at least 18 years of age * Advanced or metastatic solid tumor that has progressed on at least one prior line of treatment or is intolerant to additional effective standard therapy * Have evidence of homozygous loss of MTAP or MTAP deletion * Willing to unde...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Merck & Co., Inc. | MRK | 2 | PHASE2 | pembrolizumab, V503, GARDASIL |
| Incyte Corporation | INCY | 1 | PHASE2 | Chemotherapy, Retifanlimab |
| Novartis AG Sponsored ADR | NVS | 1 | PHASE1 | KFA115, pembrolizumab |
| Iovance Biotherapeutics Inc | IOVA | 2 | PHASE2 | E7 TCR-T cells, Aldesleukin |
| AstraZeneca PLC | AZN | 1 | — | Trastuzumab deruxtecan |